The stock has a 36-month beta value of 1.34. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for HUMA is 104.37M, and at present, short sellers hold a 28.38% of that float. On January 14, 2025, the average trading volume of HUMA was 4.83M shares.
HUMA) stock’s latest price update
Humacyte Inc (NASDAQ: HUMA)’s stock price has dropped by -5.47 in relation to previous closing price of 4.39. Nevertheless, the company has seen a loss of -15.99% in its stock price over the last five trading days. accesswire.com reported 2025-01-14 that LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between May 10, 2024, and October 17, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before January 17, 2025.
HUMA’s Market Performance
Humacyte Inc (HUMA) has seen a -15.99% fall in stock performance for the week, with a -2.81% decline in the past month and a -27.57% plunge in the past quarter. The volatility ratio for the week is 8.23%, and the volatility levels for the past 30 days are at 11.88% for HUMA. The simple moving average for the past 20 days is -9.54% for HUMA’s stock, with a -25.05% simple moving average for the past 200 days.
Analysts’ Opinion of HUMA
Many brokerage firms have already submitted their reports for HUMA stocks, with H.C. Wainwright repeating the rating for HUMA by listing it as a “Buy.” The predicted price for HUMA in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on December 20, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see HUMA reach a price target of $6. The rating they have provided for HUMA stocks is “Buy” according to the report published on December 11th, 2023.
Piper Sandler gave a rating of “Neutral” to HUMA, setting the target price at $3.50 in the report published on August 14th of the previous year.
HUMA Trading at -11.29% from the 50-Day Moving Average
After a stumble in the market that brought HUMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.38% of loss for the given period.
Volatility was left at 11.88%, however, over the last 30 days, the volatility rate increased by 8.23%, as shares surge +2.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.03% lower at present.
During the last 5 trading sessions, HUMA fell by -15.59%, which changed the moving average for the period of 200-days by +34.52% in comparison to the 20-day moving average, which settled at $4.59. In addition, Humacyte Inc saw -17.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HUMA starting from Constantino Michael T., who purchase 4,600 shares at the price of $4.39 back on Dec 04 ’24. After this action, Constantino Michael T. now owns 16,950 shares of Humacyte Inc, valued at $20,181 using the latest closing price.
Niklason Laura E, the President, CEO and Director of Humacyte Inc, purchase 1,797 shares at $4.44 during a trade that took place back on Nov 19 ’24, which means that Niklason Laura E is holding 243,851 shares at $7,979 based on the most recent closing price.
Stock Fundamentals for HUMA
Current profitability levels for the company are sitting at:
- -10.43 for the present operating margin
- 0.35 for the gross margin
The net margin for Humacyte Inc stands at -14.17. The total capital return value is set at -1.2. Equity return is now at value -850.81, with -115.74 for asset returns.
Currently, EBITDA for the company is -96.46 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 48.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.10.
Conclusion
To sum up, Humacyte Inc (HUMA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
